Clinical Outcomes and Characteristics of Patients (pts) with FLT3 –Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

In QuANTUM-R, the once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefit vs SC (median overall survival [mOS], 6.2 vs 4.7 mo [HR, 0.76 (95% CI, 0.58-0.98); P  = .02]) in R/R FLT3-ITD AML (NCT02039726). Before randomization, 25% (Q) and 23% (SC) of pts had 1 prior HSCT.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Siddhartha Ganguly, Jorge E. Cortes, Alwin Kr ämer, Mark J. Levis, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Meena Arunachalam, Guy Gammon, Arnaud Lesegretain, Derek E. Mires, Samer K. Khaled Tags: 7 Source Type: research